Ocuphire Pharma Results

In Vitro Validation of APX3330 Mechanism of Action APX3330 Reduces VEGF levels and Inflammatory Cytokines; Provides Neuronal Protection APX3330 reduces VEGF protein expression in preclinical stroke model VEGF Control VEGF % Positive area (+SE) 2.6 1.3 0.0 Ocuphire PHARMA 0.1mm VEGF APX3330 * p<0.05 n=7/group T1DM-MCAO +APX3330 APX3330 reduces pro-inflammatory cytokines in LPS stimulated macrophages TNF-α µg/mL 14000 12000 10000 8000 6000 4000 2000 0 APX3330 LPS (1 µg/mL) 14000 12000 10000 8000 5000 4000 2000 0 Hg/mL 0 ug/mL APX3330 0 ug/mL LPS (1 µg/mL) 0 ug/mL + 25 ug/mL + Increasing APX3330 dose 6.3 ug/mL 12.5 ug/mL 25 ug/mL + + + IL-6 0 ug/mL + 6.3 ug/mL 12.5 ug/mL + APX3330 increases DNA oxidative repair and neuronal protection Percentage increase in APE1 repair activity 120 115 110 105 100 95 90 N = 4 ... 12.5 25 APX3330 (μM) 0 50 APX3330 enhances Ref-1 endonuclease activity in dorsal root ganglion neurons Tao Yan et al. APX3330 Promotes Neurorestorative effects after stroke in type one diabetic rats. Aging and Disease. Vol 9, Oct 2018 Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Jedinak A, Dudhgaonkar S, Kelley MR, Sliva D. Anticancer Res. 2011 Feb;31(2):379-85. PMID: 21378315 Fehrenbacher, J. C., Guo, C., Kelley, M. R. & Vasko, M. R. DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA repair function of APE1. Neuroscience 366, 23-35, doi:10.1016/j.neuroscience.2017.09.039 (2017). 33

View entire presentation